分组1 - Evolent Health reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of +28.00% [1] - The company posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%, and this is a decline from year-ago revenues of $646.54 million [2] - Evolent Health shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has only declined by 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $544.44 million, and for the current fiscal year, it is $0.39 on revenues of $2.39 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Insights - Evolent Health reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an improvement from $0.04 per share a year ago [1] - The company experienced an earnings surprise of -50.00% and has not surpassed consensus EPS estimates in the last four quarters [2] - Evolent Health's revenues for the quarter were $479.53 million, exceeding the Zacks Consensus Estimate by 2.81%, but down from $621.4 million year-over-year [3] Financial Performance - The earnings report indicates a significant decline in stock performance, with shares down approximately 43.6% year-to-date compared to a 15.6% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $471.15 million, and for the current fiscal year, it is $0.18 on revenues of $1.87 billion [8] Industry Context - Evolent Health operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The company has a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future based on unfavorable estimate revisions [7]